Profitelligence Profitelligence · Filing Ledger Open DHR research →

Form 8-K · Current Report · Filed 2026-05-07

Danaher Corporation Shareholders Approve Incentive Plan Amendment

On May 5, 2026, Danaher Corporation's shareholders approved the Amended and Restated Danaher Corporation Omnibus Incentive Plan, which increases the share reserve by 20 million shares and extends the plan term to May 5, 2036.

Filer
Danaher Corporation DHR · NYSE
Filed
Accession
0000313616-26-000127
CIK
0000313616
Signal
High impactHealthcare

Details

The annual meeting also saw the election of eleven directors and the ratification of Ernst & Young LLP as the independent auditor for the year ending December 31, 2026.

Items reported

Item events

Reported Item

Shareholder Rights Plan (Poison Pill) Equity Plan Approved Board Member Appointed

Market reaction

Close before filing

$174.92

Next session

-2.1%

Since filing

+11.5%

Latest close

$194.98

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from DHR reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, DHR insiders reported 17 Form 4 transactions — net selling of $45K.

Full DHR insider history →

About Danaher Corporation

Danaher Corporation is a globally recognized science and technology company specializing in the development, design, and manufacturing of diverse industrial and healthcare products. With a primary focus on innovations in diagnostics, life sciences, dental, and environmental and applied solutions, Danaher serves a multitude of industries and market sectors. Its cutting-edge diagnostic equipment aids medical professionals in delivering precise healthcare, while its life sciences tools and technologies propel biomedical research and development. The company's environmental solutions also play a key role in enhancing water quality analysis and management. Headquartered in Washington, D.C., Danaher is renowned for its strong operational culture exemplified by the Danaher Business System (DBS), which emphasizes continuous improvement and sustainable innovation. This approach has solidified Danaher's presence and influence in both developing specialized solutions and improving efficiency across global markets. The company's strategic acquisitions and consistent focus on innovation have positioned it as a leader in delivering essential solutions that drive significant improvements for healthcare, research, and industrial clients.

Exchange NYSE Industry Diagnostics & Research Company website ↗

Never miss another DHR filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts